PTK2 and cancer: Currently, preclinical studies in intrahepatic cholangiocarcinoma and diffuse gastric cancer (DGC) have demonstrated the synergistic anti-cancer effects of combining FAK and CDK4/6 inhibitors (Song et al., 2021; Peng et al., 2023) These findings provide a solid theoretical foundation for future clinical studies in this area.